New insights into the function of the NLRP3 inflammasome in sarcopenia: mechanism and therapeutic strategies

• Published in: Metabolism, clinical and experimental clinical and experimental, 2024-09, Vol.158, p.155972, Article 155972
• Main Authors: Zou, Yunyi, Tang, Xiangbin, Yang, Siyuan, Chen, Zhanglin, Liu, Bin, Zhou, Zuoqiong, Peng, Xiyang, Tang, Changfa
• Format: Article
• Language: English
• Subjects: Inflammasome; NLRP3; Sarcopenia
• ISSN: 0026-0495; 1532-8600; 1532-8600
• DOI: 10.1016/j.metabol.2024.155972

Sarcopenia is one of the most common skeletal muscle disorders and is characterized by infirmity and disability. While extensive research has focused on elucidating the mechanisms underlying the progression of sarcopenia, further comprehensive insights into its pathogenesis are necessary to identify new preventive and therapeutic approaches. The involvement of inflammasomes in sarcopenia is widely recognized, with particular emphasis on the NLRP3 (NLR family pyrin domain containing 3) inflammasome. In this review, we aim to elucidate the underlying mechanisms of the NLRP3 inflammasome and its relevance in sarcopenia of various etiologies. Furthermore, we highlight interventions targeting the NLRP3 inflammasome in the context of sarcopenia and discuss the current limitations of our knowledge in this area. •Sarcopenia is a skeletal muscle disorder characterized by infirmity and disability.•The involvement of NLRP3 inflammasome in sarcopenia is deeply discussed.•An overview of the current and future therapeutic approaches targeting the NLRP3 inflammasome in sarcopenia.•The NLRP3 inflammasome can be a target for sarcopenia treatment.